DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20170326

Treatment satisfaction and safety of sitagliptin versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

Shahnaz Haque, Anand Shukla, Anil Kem

Abstract


Background: This study was designed to assess the treatment satisfaction between Sitagliptin versus Pioglitazone added to Metformin in patients with type 2 diabetes mellitus (T2DM).

Methods: We conducted a prospective, open label, randomized, parallel group study in SIMS, Hapur, U.P. Eligible patients fulfilling inclusion criteria were randomized into two groups having 25 patients in each group using tab Sitagliptin 100mg,tab Pioglitazone 30mg added to ongoing tab Metformin (500mg) therapy for 16 weeks. The follow-up visits were on weeks 4, 12 and 16.

Results: 16 weeks later, addition of Sitagliptin 100mg compared to that of Pioglitazone 30mg to ongoing Metformin therapy provided similar glycosylated haemoglobin (HbA1c) lowering efficacy in patients with T2DM with inadequate glycemic control on metformin monotherapy. Change in HbA1c in group1 was -0.656±0.21% (p<0.0001) whereas in group 2 was -0.748±0.35% (p<0.0001). Hence decrease in HbA1c from baseline was more in group2.Both treatments were well tolerated with negligible risk of hypoglycaemia. Weight loss was observed with Sitagliptin in contrast to weight gain seen in Pioglitazone.

Conclusions: In this study, Sitagliptin 100 mg along with metformin therapy in comparison to pioglitazone 30 mg plus metformin therapy was effective, well-tolerated and improved glycemic control in both the groups. Addition of pioglitazone had cause oedema and weight gain to the patients whereas sitagliptin caused weight loss in its patients.


Keywords


Metformin, Pioglitazone, Sitagliptin, Type 2 diabetes mellitus

Full Text:

PDF

References


Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-12.

Deeks ED, Scott LJ. Pioglitazone/Metformin. Drugs. 2006;66(14):1863-77.

Gallwitz B. Review of sitagliptin phosphate: a novel treatment for T2DM. Vasc Health Risk Manag. 2007;3(2):203-10.

Bradley C, Lewis K. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med. 1990;7:445-51.

Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC, UK Prospective Diabetes Study (UKPDS) Group. UKPDS 26: sulphonylurea failure in non-insulin dependent diabetic patients over six years. Diabet Med. 1998;15:297-303.

Nathan OM, Buse Ill, Davidson MB, Ferrannini E, Rury RH, Sherwin R et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.

Bo Ahren. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin Vascular Health and Risk Management. 2008;4(2):383-94.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. For the sitagliptin study 020 group* Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled with Metformin Alone. Diabetes Care. 2006;29:2638-43.

Hermansen K, Stein PP, Thornberry NA. Efficacy and safety of the DPP-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimiperide alone or on glimiperide and metformin. Diabetes obes Metab. 2007;9:733-45.

Yki-Jarvinen H. Drug therapy. Thiazolidinediones. N Engl J Med. 2004;351:1106.

Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vas Dis Res. 2006;3(3):159-65.

Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added tometformin:a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10:82-90.

Matthews DR, Charbonnel BH, Hanefeld M. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167-74.

Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Cur Med Res Opin. 2008;24(2):537-50.

Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patient’s with type 2 diabetes, Diabetes Obes Metab. 2008;10(10):959-69.

Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP for the Sitagliptin Study 074 Qroup. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194-205.

Einhorn D, Rendell M, Rosnezweig J. Pioglitazone hydrochloride in combination with metformin in the treatment of T2DM mellitus: a randomized, placebo-controlled study. Clin Ther. 2000;22:1395-409.

Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled. 011 metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin. 2006;22:751-9.

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Herman DW. For the Sitagliptin 036 Study Group. Effect of Initial Combination Therapy with Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients with T2DM. Diabetes Care. 2007;30(8):1979-87.

Rosenstock J, Baron MA, Camisasca RP. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-85.

Lawrence JM, Reckles PD. Pioglitazone. Int J Clin Pract. 2000;54:614-8.